The use of TADs through the HiC assay in Alzheimer’s disease would leave the analysis blind to any physical interactions or GWAS SNPs with this region of CR1 and it would increase the complexity of TAD boundary identification. The gene discussed is CR1; the disease is Alzheimer disease.